Rigel Pharmaceuticals Inc (RIGL) income statement
RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$42.53−0.39 (-0.91%)
Close on Nov 18, 2026Market cap $794.46MP/E 2.7Yield –
Rigel Pharmaceuticals Inc income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 91.4%
- Operating margin
- 31.5%
- Net margin
- 116.3%
- Return on equity, FY2025
- 185.9%
Financial strength
- Current ratio
- 1.94
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 63.6%
Valuation
- P/E ratio
- 2.7
- Price to sales
- 2.87
- Price to book
- 1.87
- Dividend yield
- –
See a number that looks wrong?